Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Gordon Reid and The Panic-Proof Portfolio (Stockchase Research) commented about whether GRBK-Q, AMR-N, DAL-N, AGIO-Q, AOMR-N, RIO-N, SNEX-Q, GM-N, C-N, COST-Q, MSFT-Q, GFF-N, UBER-N, F-N, BKNG-Q, META-Q, IBM-N, FCX-N, DHR-N, NVDA-Q, BRK.B-N, PFE-N, CSCO-Q, ETN-N, GOOG-Q, DELL-N are stocks to buy or sell.
- Page 2/2
- Next Page
Owns several US banks. The yield curve is steepening and the regulatory backdrop is now more favourable to the banks. The post-2008 safeguards have built huge capital in these banks and is starting to be released. Citi trades at a 24% discount to tangible book value which will compress and catch up to peers.
(Analysts’ price target is $90.30)It's all about tariffs. Despite tariffs, GM's chart shows there is an escape hatch in the tariff war and GM will come out of it well. Valuation is a very cheap 6.8x enterprise value to EBITDA. Is a cash flow machine, with 20% of market cap is in buyback share mode. They recently increased their dividend. Are well managed. Best of breed. GM has done a nice pivot into EVs, though EV consumer adoption has slowed down, but will come back.
(Analysts’ price target is $62.48)They do currency, options, hedging and are a cross-border global trading vehicle for commercial, institutional and corporate borders, any complex trading need. So, they are thriving now during lots of market volatility. Trades at only 9x PE. ROE is pushing 20%.
(Analysts’ price target is $128.00)
Offering diversification globally into materials such as iron ore, aluminum, copper and lithium, we reiterate RIO as a TOP PICK. Analysts expect their copper production will grow over 30% over the next 3 years. It trades at 10x earnings, under 2x book and supports a ROE of 20%. The robust dividend is backed by a payout ratio under 60% of cash flow. We continue to recommend a stop at $58, looking to achieve $81 — upside over 25%. Yield 5.9%
(Analysts’ price target is $81.13)We reiterate this first mortgage company as a TOP PICK. Interest revenues grew 30% over the year. The company was able to offer 5 securitized offerings over the year - bettering their goal of one per quarter. It trades at 8x earnings, at book value and supports a ROE of 11%. We recommend trailing up the stop (from $8) to $9, looking to achieve $12 — upside potential of 20%. Yield 7.6%
(Analysts’ price target is $12.04)We reiterate AGIO as a TOP PICK. The developer of cancer treatment drugs expects two more products to go commercial over the next year- each with the potential to grow cash flows substantially. It trades at 3x earnings, 1.2x book and supports and supports a robust 57% ROE. We recommend trailing up the stop (from $21) to $25, looking to achieve $41 — upside potential of 28%. Yield 0%
(Analysts’ price target is $54.57)Our PAST TOP PICK with DAL has triggered its stop at $60. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment gain of 27%.
Our PAST TOP PICK with AMR has triggered its stop at $140. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 29%.
Sensitive to interest rates. The housing market has frozen which will freeze GFF. As long-term holder, wait for a better environment. But if you believe rates will stay high (higher inflation), sell this, but he doesn't believe. Rather, rates will continue to come down.